Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to buy right now. Following the company’s fiscal second-quarter 2026 financial results, Oppenheimer reaffirmed its Outperform rating on Immunovant, Inc. (NASDAQ:IMVT) on November 11 with a price target of $54. The company’s reported earnings per share of -$0.73 fell short of the -$0.71 consensus estimate. With$4.4 billion in cash and no debt on its balance sheet, Immunovant, Inc. (NASDAQ:IMVT) maintains a strong capital position in d ...